Figure 4 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib

類似資料

• Figure 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
  著者:: Christian Rolfo (17314293)
  出版事項: (2025)
• Figure 2 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
  著者:: Christian Rolfo (17314293)
  出版事項: (2025)
• Figure 3 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
  著者:: Christian Rolfo (17314293)
  出版事項: (2025)
• Table 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
  著者:: Christian Rolfo (17314293)
  出版事項: (2025)
• Table 2 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
  著者:: Christian Rolfo (17314293)
  出版事項: (2025)